Allergic Fungal Rhinosinusitis

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

CLINICAL_TRIALS withdrawal · 2024-07-25
Clinical Trial Update: Study of Dupilumab 300 mg Every Other Week After Endoscopic Sinus Surgery in Patients With Allergic Fungal Rhinosinusitis (AFRS) on a Background Therapy With Intranasal Corticosteroid Spray [Phase 3]
A Phase 3 trial evaluating dupilumab for Allergic Fungal Rhinosinusitis after endoscopic sinus surgery has been withdrawn.